Lorbrena Tablet, Film Coated
Product Images NDC 63539-927
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lorbrena (NDC 63539-927). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by U.s. Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Lorbrena 02)
This is a comparison between LORBRENA (N= 149) and Crizotinib (N=147) in terms of median survival. LORBRENA achieved a median that was not reached, while Crizotinib achieved a median of 9.3 months. The hazard ratio for LORBRENA was 0.28 with a 95% confidence interval of (0.19, 0.41) and p-value < 0.0001. The graph shows the survival time (months) for each group.*
Logo (Lorbrena 03)
Logo (Lorbrena 04)
Principal Display Panel (25 mg Tablet Bottle Label Sample)
This is a prescription medication called Lorbrena (lorlatinib) that comes in the form of tablets. It is recommended to store the medication at room temperature between 20°C to 25°C (68°F to 77°F) or permissible between 10°C to 30°C (50°F to 86°F), and dispense in child-resistant containers. The dosage and specific use instructions can be found in the accompanying prescribing information. Each tablet contains 25mg of lorlatinib, and it is distributed by U.S. Pharmaceuticals Pfizer Inc. in New York. The provided details include a professional sample not for sale, NDC number 63539-927-0, LOT number, and GTIN number.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.